Brief: Point Biopharma Confirms No Disruptions To The Manufacturing And Clinical Supply For The 177Lu-Pnt2002 Splash Trial, A Phase 3 Study In Patients With Metastatic Castration Resistant Prostate Cancer (Mcrpc)

POINT Biopharma Global

07/03/2023 12:46

March 7 (Reuters) - POINT Biopharma Global Inc  PNT.O :
    * POINT BIOPHARMA CONFIRMS NO DISRUPTIONS TO THE
MANUFACTURING AND
CLINICAL SUPPLY FOR THE 177LU-PNT2002 SPLASH TRIAL, A PHASE 3
STUDY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE
CANCER (MCRPC)
    * POINT BIOPHARMA GLOBAL- SPLASH CLINICAL TRIAL FOR
PSMA-TARGETED
PNT2002 PROGRAM IS NOT EXPERIENCING ANY MANUFACTURING OR DRUG
SUPPLY ISSUES OR DELAYS
    * POINT BIOPHARMA GLOBAL INC- IN-HOUSE PRODUCTION OF
NO-CARRIER-ADDED LU AT POINT'S INDIANAPOLIS FACILITY IS EXPECTED
TO COMMENCE BY END OF 2023
    * POINT BIOPHARMA GLOBAL: SPLASH CLINICAL TRIAL FOR
PSMA-TARGETED
PNT2002 PROGRAM IS NOT EXPERIENCING ANY MANUFACTURING OR DRUG
SUPPLY ISSUES OR DELAYS

Source text for Eikon:  ID:nGNX2kgZ3m 
Further company coverage:  PNT.O 

 ((Reuters.Briefs@thomsonreuters.com;))